NEW YORK (GenomeWeb) – Investment firm BTIG today upgraded Agilent Technologies' stock to a Buy rating on improving confidence in the company's outlook. 

Analyst Dane Leone upgraded Agilent from an earlier Neutral rating and set the 12-month price target on the firm's stock at $52. In a research note, he cited Agilent's China business, and said that after two years of having to deal issues in the region those operations are poised to improve.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.